The results obtained through the evaluation of the pharmacological effects of marker expression between the 2-AEH2P + GM-CSF association enable new clinical protocols in search of therapeutic strategies targeting mitochondria and cancer immunotherapy. This evidence concerns the gene CSF2 and cancer.